News

Video

Facing Challenges and Excitement for Immunotherapy in GI Cancers

The science behind immunotherapy and gastrointestinal cancers is not quite perfected yet, but one subset of patients is seeing remarkable results.

Gregory Beatty, M.D., Ph.D., assistant professor at the University of Pennsylvania Perelman School of Medicine, discusses challenges of using immunotherapy to treat gastrointestinal (GI) cancers.

The majority of the immune system is located in the gut, Beatty says, and every single day, it encounters many pathogens and has to decide to fight them or not. Because of this, it might be difficult to spark the immune system when a foreign body, like cancer, is located there.

However, there are some subsets of GI cancers whose tumors have DNA mismatch repair — which ultimately leads to microsatellite instability – that look more like an invader, thus activating the immune response. This group of patients has seen astounding results with the use of checkpoint inhibitors.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Image of two doctors and text.
Related Content